Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [6469]

ASH 2017: AML study reports high response rates with combination targeted therapy

ASH 2017: AML study reports high response rates with combination targeted therapy

NICE recommends lenvatinib for the treatment of advanced renal cell carcinoma (RCC)

NICE recommends lenvatinib for the treatment of advanced renal cell carcinoma (RCC)

ASH 2017: Addition of targeted drug reduces risk of first-line treatment failure in advanced Hodgkin lymphoma

ASH 2017: Addition of targeted drug reduces risk of first-line treatment failure in advanced Hodgkin lymphoma

ASH 2017: Rapid responses, few adverse effects seen with targeted agent in Phase I trial in rare blood disorder

ASH 2017: Rapid responses, few adverse effects seen with targeted agent in Phase I trial in rare blood disorder

ASH 2017: Sustained benefit with Ibrutinib in r/r MCL

ASH 2017: Sustained benefit with Ibrutinib in r/r MCL

SABCS 2017: Lymph node surgery may raise risk of arm morbidity in younger women

SABCS 2017: Lymph node surgery may raise risk of arm morbidity in younger women

SABCS 2017: PARP inhibitor improves progression-free survival in patients with advanced breast cancers and BRCA mutations

SABCS 2017: PARP inhibitor improves progression-free survival in patients with advanced breast cancers and BRCA...

Important bacterial discovery in oral pre-cancer condition

Important bacterial discovery in oral pre-cancer condition

Novel pathway to suppress virus-induced cancers

Novel pathway to suppress virus-induced cancers

Mechanism identified behind enzyme involved in liver and other human cancers

Mechanism identified behind enzyme involved in liver and other human cancers

More from ecancer